Mizuho Cuts Immunocore (NASDAQ:IMCR) Price Target to $33.00

Immunocore (NASDAQ:IMCR) had its price target lowered by Mizuho from $38.00 to $33.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Mizuho’s price objective points to a potential upside of 25.75% from the company’s current price.

A number of other research firms have also weighed in on IMCR. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research report on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price target on shares of Immunocore in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Immunocore presently has an average rating of “Moderate Buy” and a consensus price target of $65.18.

Immunocore Stock Down 3.7 %

Shares of IMCR stock traded down $1.02 on Monday, reaching $26.24. 404,118 shares of the stock were exchanged, compared to its average volume of 293,061. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a twelve month low of $24.84 and a twelve month high of $63.94. The business’s 50 day moving average price is $29.80 and its 200 day moving average price is $30.77. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -27.51 and a beta of 0.75.

Insider Buying and Selling

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the company’s stock in a transaction on Monday, March 17th. The stock was bought at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the transaction, the director now owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.10% of the stock is owned by corporate insiders.

Institutional Trading of Immunocore

Institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in shares of Immunocore during the 4th quarter worth about $25,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after purchasing an additional 960 shares during the last quarter. NEOS Investment Management LLC increased its position in Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after purchasing an additional 1,102 shares during the period. Tema Etfs LLC acquired a new position in shares of Immunocore in the 4th quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC grew its position in shares of Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after buying an additional 3,238 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.